临床和实验室研究年鉴

  • 国际标准期刊号: 2386-5180
  • 期刊 h 指数: 17
  • 期刊引用分数: 6.26
  • 期刊影响因子: 5.31
索引于
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 引用因子
  • 研究期刊索引目录 (DRJI)
  • 普布隆斯
  • 欧洲酒吧
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
分享此页面

抽象的

Convalescent Plasma Therapy for Prophylaxis and Treatment of COVID-19: A Systematic Research of Facts and Files, A Narrative Review

Koduri Sridevi, Amit Munjal, Ajay Chandran, Nachiappan S,Praveena Raman, Sukriti Bhalla, Sourya Kumar, Abhishek Singh Nayyar

Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same.